Seriously all, this is a direct quote of Tharlows CXS post:
-------------------
"I can't believe this is trading under $2. Drug has huge potential, and this could easily be over $3 within 12 months. And adding a big-hitting partner to the mix makes this a simple pick for a home run.
A hidden gem."
-------------------
Go check out the current clinical trials for Ceflatonin (ChemGenexs lead): It's in a phase-II/III for a subset of Chronic Myeloid Leukaemia patients that represent less than 5% of all cases. Considering there are only 4,000 odd new cases per year in the USA, that comes out to a target market of 200 patients per year...WOW! On the other hand, liver cancer has an incidence of about 20,000 cases per year in the USA of which 15-20% are eligible for surgery - a target market of 3,000 to 4,000 cases per year (that's 20x the potential of ChemGenex's drug) plus many more in Asia.....plus there's trialing of PI-88 in lung, prostate, they are potentially huge markets.
Go figure. Tharlow makes NO SENSE and is INCONSISTENT in his analysis.
Nong.
- Forums
- ASX - By Stock
- link to research report
Seriously all, this is a direct quote of Tharlows CXS...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PGL (ASX) to my watchlist
|
|||||
Last
44.0¢ |
Change
-0.005(1.12%) |
Mkt cap ! $72.46M |
Open | High | Low | Value | Volume |
44.0¢ | 44.0¢ | 44.0¢ | $10.48K | 23.83K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 1124106 | 44.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.5¢ | 1389 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 1124106 | 0.440 |
3 | 145300 | 0.435 |
1 | 55597 | 0.425 |
1 | 83416 | 0.420 |
1 | 16000 | 0.415 |
Price($) | Vol. | No. |
---|---|---|
0.445 | 1389 | 1 |
0.450 | 121719 | 5 |
0.460 | 16399 | 1 |
0.490 | 21811 | 2 |
0.500 | 2000 | 1 |
Last trade - 10.10am 12/07/2024 (20 minute delay) ? |
Featured News
PGL (ASX) Chart |